Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL* protocol

Juan José Cerezo-Manchado1, Olga Meca Birlanga2, Luis García de Guadiana Romualdo3, Ignacio Gil-Ortega4, Antonio Martínez Francés1, Teodoro Iturbe-Hernandez1

1Department of Hematology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain; 2Department of Pneumology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain; 3Laboratory Department, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain; 4Department of Cardiology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain

Abstract

COVID-19 increases the risk of atrial fibrillation (AF) and thrombotic complications, particularly in severe cases, leading to higher mortality rates. Anticoagulation is the cornerstone to reduce thromboembolic risk in patients with AF. Considering the risk of hepatotoxicity in patients with severe COVID-19 as well as the risk of drug–drug interactions, drug-induced hepatotoxicity and bleeding, the ANIBAL protocol was developed to facilitate the anticoagulation approach at discharge after COVID-19 hospitalization. However, since the publication of the original algorithm, relevant changes have occurred. First, treatment of COVID-19 pneumonia has been modified with the use of dexamethasone or remdesivir during the first week in patients that require oxygen therapy, and of dexamethasone and/or tocilizumab or baricitinib during the second week in patients that necessitate supplementary oxygen or with a high inflammation state, respectively. On the other hand, metabolic syndrome is common in patients with AF as well as metabolic-associated fatty liver disease, and this could negatively impact the prognosis of patients with COVID-19, including high transaminase levels in patients treated with immunomodulators. The EHRA guidelines update also introduce some interesting changes in drug–drug interaction patterns with the reduction of the level of the interaction with dexamethasone, which is of paramount importance in this clinical context. Considering the new information, the protocol, named ANIBAL II, has been updated. In this new protocol, the anticoagulant of choice in patients with AF after COVID-19 hospitalization is provided according to three scenarios: with/without dexamethasone treatment at discharge and normal hepatic function, transaminases ≤2 times the upper limit of normal, or transaminases >2 times the upper limit of normal.

Keywords: atrial fibrillation, COVID-19, dabigatran, direct oral anticoagulants, hepatotoxicity, MAFLD, metabolic syndrome.

Citation

Cerezo-Manchado JJ, Meca Birlanga O, Garcia de Guadiana Romualdo L, Gil-Ortega I, Martinez Francés A, Iturbe-Hernandez T. Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL* protocol. Drugs Context. 2022;11:2021-9-4. https://doi.org/10.7573/dic.2021-9-4

Introduction

Atrial fibrillation (AF) is common in patients with COVID-19. Thus, a recent meta-analysis of 31 studies found that ~8% of patients with COVID-19 also have AF, and thus have a worse prognosis.1 The ANIBAL (Anticoagulación al alta tras una Neumonía Inducida por Covid-19 y Basada en las Alteraciones Laboratoriales de la función hepática y metabólica – Anticoagulation at COVID-19 pneumonia discharge based on hepatic and metabolic laboratory alterations) protocol recently published (Figure 1) considered dabigatran as the oral anticoagulant of choice in this clinical setting due to the lower risk of hepatotoxicity, drug–drug interactions and the availability of a specific reversal agent.2 However, as the therapeutic approach of COVID-19 pneumonia has substantially changed during this period, the ANIBAL protocol was updated. Whereas certain drugs used during the first months of the COVID-19 pandemic, such as hydroxychloroquine, azithromycin or lopinavir/ritonavir, have become obsolete, current hospital protocols include remdesivir as the antiviral therapeutic of***

*The name of this great Carthaginian military general has been chosen for the protocol as a tribute by the authors, as they carry out their healthcare work in Cartagena
choice during the first week of COVID-19 pneumonia. In addition, corticosteroids, particularly dexamethasone, have also been considered as the first-line therapy in patients hospitalized with COVID-19 pneumonia, with a modulation of the risk of drug–drug interactions according to the European Heart Rhythm Association (EHRA) update regarding the use of direct oral anticoagulants (DOACs) in patients with AF. The current protocol in our hospital (University Hospital Santa Lucía, Cartagena, Spain) for the treatment of COVID-19 pneumonia (Figure 2) is based on current recommendations according to available evidence. In addition, the anticoagulation protocol during hospitalization and at discharge according to different clinical circumstances is also presented (Figure 2). During the first week, remdesivir and dexamethasone are indicated in symptomatic patients that require oxygen therapy to improve prognosis. During the second week from the onset of

**Figure 1. Algorithm of management of patients with atrial fibrillation at discharge after COVID-19 pneumonia.**

**The ANIBAL I protocol.**

- **Normal hepatic function/transaminases ≤ 2 x ULN, risk of drug–drug interactions, drug-induced hepatotoxicity or bleeding (consider specific reversal agent)**
  - Dabigatran: If CrCl ≥30 ml/min (with dose adjustment according to SPC)
  - Edoxaban 30 mg: If CrCl >15 to <30 ml/min
  - LMWH (therapeutic doses) adjusted to weight and renal function

**Transaminases >2 x ULN**

CrCl, creatinine clearance; LMWH, low-molecular-weight heparin; ULN, upper limit of normal. Adapted from ref. 2

**Figure 2. Therapeutic approach of patients hospitalized with COVID-19 pneumonia at the University Hospital Santa Lucía, Cartagena, Spain.**

- **FIRST WEEK**
  - Dexamethasone 6 mg iv/oral for 10 days
  - Remdesivir: 200 mg iv loading dose; followed by 100 mg iv daily (days 2-5)

  Indicated in patients with <7 days of symptoms that require oxygen therapy (no high flow oxygen or mechanical ventilation)

- **SECOND WEEK**
  - ≥7 days, PaFi <300: tocolizumab\(^1\) if CRP >7.5 mg/dL/baricitinib\(^2\) if CRP <7.5 mg/dL
  - If progression: dexamethasone 20 mg for 5 days 10 mg for 5 days (subsequent dose de-escalation)/methylprednisolone 250 mg iv for 3 days

\(^1\)Tocilizumab: >75 kg: 600 mg iv; <75 kg 400 mg
\(^2\)Baricitinib: 4 mg oral 7–14 days; 2 mg oral if <75 years or CrCl 30–60 ml/min

CrCl, creatinine clearance; CRP, C-reactive protein; PaFi, inspired oxygen fraction. Reproduced from ref. 2 with permission.
REVIEW – Dabigatran in atrial fibrillation after COVID-19

Cerezo-Manchado JJ, Meca Birlanga O, et al. Drugs Context. 2022;11:2021-9-4. https://doi.org/10.7573/dic.2021-9-4
ISSN: 1740-4398

3 of 11

Box 1. Considerations for anticoagulation of patients with atrial fibrillation at discharge after COVID-19 pneumonia.

- ‘Biological’ safety of DOAC versus vitamin K antagonist as no anticoagulation control is required.
- Hepatotoxicity of COVID-19 and antiviral therapy in short-term and long-term evolution as well as the presence of possible hepatic steatosis associated with metabolic syndrome.
- Treatment with dexamethasone at discharge may reduce plasmatic levels of DOAC when they are used concomitantly.
- Renal function at discharge (eGFR according to Cockroft–Gault).
- Thrombogenicity of COVID-19: choose the most potent DOAC, preferably a twice daily dose.
- Arrhythmogenicity of COVID-19: risk of new-onset atrial fibrillation that requires anticoagulation (choose DOAC to facilitate health education and adherence).
- DOAC with specific reversal agent to reduce the impact of the underuse of the health system during the COVID-19 pandemic.

DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate. Reproduced from ref. 2 with permission.
‘Biological’ safety of DOACs (versus VKA)

The introduction of DOACs in Spain has been restricted due to economic politics as reimbursement has been limited to some specific indications. This has led to a lower proportion of patients taking DOACs compared with other European countries. However, as patients taking VKA require periodic monitoring of anticoagulant activity (i.e. every 2–6 weeks, according to INR control) and this increases SARS-CoV-2 exposure, the Spanish Sanitary Authorities have reduced the restrictions of switching from VKA to DOACs, leading to a higher prescription of DOACs and, secondarily, to a reduction of outcomes. Of note, a recent study reported that, in Spain, the progressive higher prescription of DOACs has been associated with a decrease in the incidence of AF-related ischaemic stroke. It is not only important to reduce the risk of contagion for patients but also for healthcare professionals as they are an important risk group given their high exposure level. In fact, the main concern of healthcare professionals is contagion, particularly in the workplace.

The use of DOACs instead of VKA thus reduces exposure to SARS-CoV-2 infection for both patients and professionals.

COVID-19-related hepatotoxicity, antiviral drugs and immunomodulatory therapy, previous hepatic disease such as MAFLD

Although uncommon, drug-induced liver injury associated with the use of tocilizumab, remdesivir or baricitinib has been described. In this context, the use of those drugs with a lower risk of drug–drug interactions may be preferable. Thus, no clinically significant interaction is expected between dabigatran and tocilizumab, baricitinib, or remdesivir (Table 1). With regard to oral anticoagulants in patients with AF and liver injury, a study showed that after 1-year follow-up, hepatic injury hospitalization rates were lower in initiators of DOACs versus in those taking warfarin (HR 0.57, 95% CI 0.46–0.71) and, of available DOACs, dabigatran had the lowest risk compared with warfarin (Figure 3). However, not all studies have shown differences regarding the risk of acute liver injury and DOACs compared with VKA in patients with AF.

On the other hand, we consider that the systematic search of MAFLD in patients with metabolic syndrome with imaging techniques, particularly echography, and if positive, to rule out the presence of hepatic fibrosis with indirect methods (i.e. FibroScan) may not be useful in routine practice. A better approach seems to be to consider that patients with AF and metabolic syndrome may have or at least are at high risk of MAFLD. In this context, it would be preferable to prescribe a first-line oral anticoagulant, such as dabigatran, that is not metabolized by CYP 450 and is less harmful to the liver.

Use of DOACs with a low risk of dexamethasone interaction

Dexamethasone is a moderate CYP 3A4 inducer and an inducer of P-glycoprotein and may potentially have a clinically significant interaction with DOACs, leading to a reduction of serum concentrations of DOACs and, consequently, to a reduction of their efficacy. This is very relevant considering the high thrombogenicity of COVID-19. The EHRA update states the low risk of drug–drug interactions with those DOACs that are not preferentially metabolized by the CYP 450 pathway. In this context, the widespread use of dexamethasone in patients with COVID-19, either initially or later in case of progression, including at discharge, promotes the use of dabigatran or edoxaban due to the low risk of drug–drug interactions.

Remarkably, this change allows the use of dabigatran or edoxaban immediately at discharge, without requiring low-molecular-weight heparin bridge therapy. This is the most important novelty compared to the first ANIBAL protocol.

Renal function at discharge (according to Cockcroft–Gault formula)

First, it should be emphasized that the estimation of glomerular filtration rate should be performed by means of the Cockcroft–Gault formula as this was the method used in the pivotal clinical trials with DOACs (versus warfarin) to determine renal function, and approval by the regulatory agencies was performed considering this method.

In addition, it has been reported that, in elderly patients, the use of other methods, such as the CKD-EPI equation instead of the Cockcroft–Gault formula, to calculate renal function could overestimate the glomerular filtration rate, leading to mistakes in the dosage of DOACs and a higher risk of side effects.

Finally, it has been shown that the use of some DOACs, such as dabigatran and rivaroxaban but not of apixaban, could be associated with a lower risk of renal adverse events compared to warfarin. However, it should be also considered that, amongst patients with chronic kidney disease, the risk of stroke or bleeding could differ according to the DOAC used.

Thrombogenicity and COVID-19

Patients with COVID-19 have a higher risk of pulmonary embolism and deep vein thrombosis. Although treatment with low-molecular-weight heparin reduced the risk of pulmonary embolism or venous thrombosis during COVID-19 hospitalization, the dose to be used remains a subject of debate, particularly in critically ill patients, as well as the identification of risk factors that may recognize those patients that would benefit more from high-dose low-molecular-weight heparin. Similarly, it remains unclear which is the best ambulatory thromboprophylaxis approach after discharge.
Table 1. Potential drug–drug interactions of anticoagulants with current COVID-19 therapies.

| Treatment for COVID-19 | Anticoagulant | Drug–drug interaction                                                                                                                                                                                                 | Recommendation                                                                                          |
|------------------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Dexamethasone          | VKA           | • The efficacy of VKA can be enhanced, promoting bleeding risk  
• Potential clinically significant interaction                                                                                                                      | • Close INR monitoring is recommended                                                                 |
| Apixaban               |               | • Apixaban is metabolized by CYP 3A4 and dexamethasone is a moderate CYP 3A4 inducer, decreasing apixaban levels  
• Potential clinically significant interaction                                                                                                                  | • Consider changing to another anticoagulant (i.e. LMWH) whilst concomitant treatment, up to 14 days after dexamethasone interruption |
| Dabigatran             |               | • Dabigatran is not metabolized by CYP 450  
• The prodrug of dabigatran is a substrate of P-gp, and dexamethasone is an inducer of P-gp in pre-clinical models  
• Potential clinically significant interaction                                                                                                                |                                                                                                         |
| Edoxaban               |               | • Edoxaban is minimally metabolized by CYP 3A4/5  
• Edoxaban is a substrate of P-gp, and dexamethasone is an inducer of P-gp in pre-clinical models  
• Potential clinically significant interaction                                                                                                                |                                                                                                         |
| Rivaroxaban            |               | • Rivaroxaban is partly metabolized in the liver by CYP 3A4, CYP 1A2, and hydrolytic enzymes and partly eliminated unchanged in urine by P-gp and BCRP  
• Dexamethasone is a moderate CYP 3A4 inducer and an inducer of P-gp  
• Potential clinically significant interaction                                                                                                                |                                                                                                         |
| Enoxaparin             |               | • No clinically significant interaction is expected  
• No action is required                                                                                                                                          |                                                                                                         |
| Tocilizumab            | VKA           | • VKA are mainly metabolized by CYP 2C9  
• IL-6 (tocilizumab target) may suppress expression/activity of cytochromes  
• Tocilizumab, per se, has no effect on cytochromes, but normalizes cytochrome activity (via IL-6 inhibition)  
• Potential weak interaction                                                                                                                                  | • INR monitoring is recommended (dose increase may be required)                                        |
| Apixaban               |               | • Apixaban is metabolized by CYP 3A4  
• IL-6 (tocilizumab target) may suppress expression/activity of cytochromes  
• Tocilizumab, per se, has no effect on cytochromes, but normalizes cytochrome activity (via IL-6 inhibition)  
• Potential weak interaction                                                                                                                                  | • Dose increase may be required                                                                                                                                   |
Table 1. (Continued)

| Treatment for COVID-19 | Anticoagulant       | Drug–drug interaction                                                                 | Recommendation |
|------------------------|---------------------|----------------------------------------------------------------------------------------|----------------|
| Tocilizumab (Cont.)    | Rivaroxaban         | • Rivaroxaban is partly metabolized in the liver by CYP 3A4, CYP 1A2 and hydrolytic enzymes and partly eliminated unchanged in urine by P-gp and BCRP  
• IL-6 (tocilizumab target) may suppress expression/activity of cytochromes  
• Tocilizumab, per se, has no effect on cytochromes but normalizes cytochrome activity (via IL-6 inhibition)  
• Potential weak interaction | • No action is required |
|                        | Dabigatran          | • No clinically significant interaction is expected                                      |                |
|                        | Edoxaban            |                                                                                       |                |
|                        | Enoxaparin          |                                                                                       |                |
| Baricitinib            | VKA Apixaban        | • No clinically significant interaction is expected                                      | • No action is required |
|                        | Dabigatran          |                                                                                       |                |
|                        | Edoxaban            |                                                                                       |                |
|                        | Rivaroxaban         |                                                                                       |                |
|                        | Enoxaparin          |                                                                                       |                |
| Remdesivir             | VKA Apixaban        | • No clinically significant interaction is expected                                      | • No action is required |
|                        | Dabigatran          |                                                                                       |                |
|                        | Edoxaban            |                                                                                       |                |
|                        | Rivaroxaban         |                                                                                       |                |
|                        | Enoxaparin          |                                                                                       |                |

INR, International Normalized Ratio; LMWH, low-molecular-weight heparin; P-gp, P-glycoprotein; VKA, vitamin K antagonists. Adapted from ref.41
The European Society of Cardiology recommends that, in patients with AF during COVID-19 pandemic, unless contraindicated, full therapeutic anticoagulation for the prevention of stroke should be administered to men and women with a CHA\textsubscript{2}DS\textsubscript{2}-VASc of ≥2/3, and anticoagulation should be considered in case of CHA\textsubscript{2}DS\textsubscript{2}-VASc 1/2.\textsuperscript{33} As a result, it is not clear whether anticoagulation should also be recommended during COVID-19 due to the high thrombogenicity of this period and whether this should be maintained over time after COVID-19 recovery.

Risk of arrhythmias and COVID-19

COVID-19 affects both the respiratory system and the cardiovascular system. Patients with a prior cardiovascular condition have a higher risk of mortality and severe COVID-19. In addition, cardiovascular complications of COVID-19 include arrhythmias, particularly AF, cardiac injury, myocarditis, heart failure, arterial/venous thrombosis and acute coronary syndrome.\textsuperscript{58} A recent study that analysed 160 consecutive patients hospitalized due to COVID-19 showed that patients with new-onset AF had a higher incidence of thromboembolic events, bleeding, a combined endpoint of thrombosis and death, and longer hospital stays, indicating that an active search of AF should be performed in patients hospitalized with COVID-19 and the need of anticoagulation in case of development of AF.\textsuperscript{59}

DOACs and specific reversal agents

During the COVID-19 pandemic, particularly during the lockdown period, there has been a reduction of hospital admissions for cardiovascular disease, including acute coronary syndrome, heart failure or AF, leading to an increase in adverse outcomes.\textsuperscript{60,61} This could be related, at least in part, to the lack of seeking for medical attention, despite symptoms, due to concerns about COVID-19 contagion. Thus, a study that analysed data from nationwide Danish registries showed a lower incidence of new-onset AF during the 3 weeks of lockdown compared with the previous year, with a 47% drop in total numbers, but with a higher risk of ischaemic stroke and death amongst patients with new-onset AF.\textsuperscript{61} As a result, during the COVID-19 pandemic, there has been an underdiagnosis of AF, increasing the risk of severe complications.
In order to reduce the risk of complications during the COVID-19 pandemic, and in some way to counteract the harmful effects of the underuse of health systems, the use of DOACs, such as dabigatran, which have a specific agent that rapidly reverses the effects of the drug in case of life-threatening bleeding, should be considered as first choice.\(^7\)

**Update of the protocol**

With all this new information, we have proposed an updated protocol, the ANIBAL II algorithm for the management of patients with AF at discharge after COVID-19 pneumonia (Figure 4). This algorithm has three scenarios: Scenario 1: with or without dexamethasone and normal hepatic function; Scenario 1: with or without dexamethasone and transaminases ≤2 × upper limit of normal (ULN); Scenario 1: with or without dexamethasone and transaminases >2 × ULN. In those patients with transaminases >2 × ULN, therapeutic doses of low-molecular-weight heparin are recommended as is switching to oral anticoagulation in case of transaminases ≤2 × ULN. In all other cases, dabigatran is recommended if the estimated glomerular filtration rate is ≥30 mL/min or edoxaban 30 mg is recommended if the estimated glomerular filtration rate >15 to <30 mL/min.

**Conclusions**

The application of the ANIBAL I protocol has had a positive impact in routine practice as it has allowed a holistic approach in the management of anticoagulation in patients with AF after COVID-19 hospitalization, considering different important variables with relevant impact on the clinical course of patients such as hepatic function and the risk of drug–drug interactions, drug-induced hepatotoxicity, or bleeding, as well as considering the availability of a specific reversal agent. The impact of the ANIBAL I protocol is currently being analysed in a Spanish multicentre study. However, as the management of COVID-19 pneumonia has been revised in the last months (i.e. using remdesivir, tocilizumab, baricitinib and dexamethasone) and as greater knowledge about the impact that COVID-19 may have on patients with AF and MAFLD has been obtained, the protocol has been updated as delineated herein.

---

**Contributions:** All authors contributed extensively to the work presented in this paper. All authors have contributed significantly to the conception, design, or acquisition of data, or analysis and interpretation of data. All authors have participated in drafting, reviewing, and/or revising the manuscript and have approved its submission. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Disclosure and potential conflicts of interest:** JJCM reports non-financial support from Boehringer Ingelheim during the conduct of the study and personal fees from Boehringer Ingelheim, Pfizer, Bayer and Daichii-Sankyo outside the submitted work. The rest of the authors have nothing to disclose. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: [https://www.drugsincontext.com/wp-content/uploads/2021/12/dic.2021-9-4-COI.pdf](https://www.drugsincontext.com/wp-content/uploads/2021/12/dic.2021-9-4-COI.pdf)
Acknowledgements: Content Ed provided writing and editorial support, which was funded by the Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, though an unrestricted grant from Boehringer Ingelheim Spain. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to Boehringer Ingelheim substances, as well as intellectual property considerations.

Funding declaration: Funded by the Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, though an unrestricted grant from Boehringer Ingelheim Spain.

Copyright: Copyright © 2022 Cerezo-Manchado JJ, Meca Birlanga O, García de Guadiana Romualdo L, Gil-Ortega I, Martínez Francés A, Iturbe-Hernandez T. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2022 Cerezo-Manchado JJ, Meca Birlanga O, García de Guadiana Romualdo L, Gil-Ortega I, Martínez Francés A, Iturbe-Hernandez T. https://doi.org/10.7573/dic.2021-9-4. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/dabigatran-in-patients-with-atrial-fibrillation-after-covid-19-hospitalization-an-update-of-the-anibal-protocol

Correspondence: Juan José Cerezo-Manchado, Department of Hematology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain. C. Minarete, s/n, 30202 Cartagena, Murcia, Spain. Email: jjcerezo@ucam.edu

Provenance: Submitted; externally peer reviewed.

Submitted: 5 October 2021; Accepted: 2 December 2021; Publication date: 24 January 2022.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Romiti GF, Corica B, Lip GYH, Proietti M. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. J Clin Med. 2021;10:2490. https://doi.org/10.3390/jcm10112490

2. Iturbe-Hernández T, García de Guadiana RL, Gil Ortega I, et al. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID19 infection: the ANIBAL protocol. Drugs Context. 2020;9:1–12. https://doi.org/10.7573/drsc.2020-8-3

3. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21:167–179. https://doi.org/10.1007/s10238-020-00671-y

4. Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142:112015. https://doi.org/10.1016/j.biopharma.2021.112015

5. Lee HW, Park J, Lee JK, Park TY, Heo EY. The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia. Tuberc Respir Dis. 2021;84:217–225. https://doi.org/10.4046/trd.2021.0009

6. Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE. 2021;16:e0252057. https://doi.org/10.1371/journal.pone.0252057

7. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676. https://doi.org/10.1093/europace/euab065

8. Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic syndrome pathophysiology and predisposing factors. Int J Sports Med. 2021;42:199–214. https://doi.org/10.1055/a-1263-0898

9. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues related to Definition. Circulation. 2004;109:433–438. https://doi.org/10.1161/01.CIR.000011245.75752.C6

10. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013;62:697–703. https://doi.org/10.1016/j.jacc.2013.05.064

11. He D, Zhang X, Chen S, et al. Dynamic changes of metabolic syndrome alter the risks of cardiovascular diseases and all-cause mortality: evidence from a prospective cohort study. Front Cardiovasc Med. 2021;8:706999. https://doi.org/10.3389/fcvm.2021.706999

12. Ahn HJ, Han KD, Choi EK, et al. Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study. Cardiovasc Diabetol. 2021;20:20. https://doi.org/10.1186/s12933-021-01215-8
13. Lee SY, Lee SR, Choi EK, et al. Association between change in metabolic syndrome status and risk of incident atrial fibrillation: a nationwide population-based study. *J Am Heart Assoc.* 2021;10:e020901. https://doi.org/10.1161/JAHA.121.020901

14. Mohanty S, Mohanty P, Di Biase L, et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. *J Am Coll Cardiol.* 2021;59:1295–1301. https://doi.org/10.1016/j.jacc.2021.11.051

15. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology.* 2020;158:1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312

16. Dongiovanni P, Meroni P, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. *Expert Rev Gastroenterol Hepatol.* 2020;14:867–872. https://doi.org/10.1080/17474124.2020.1801417

17. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. *Eur J Clin Invest.* 2020;50:e13338. https://doi.org/10.1111/eci.13338

18. Ji D, QWin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. *J Hepatol.* 2020;73:451–453. https://doi.org/10.1016/j.jhep.2020.06.001

19. Targher G, Mantovani A, Byrne CD, et al. Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. *Diabetes Metab.* 2020;46(6):505–507. https://doi.org/10.1016/j.diabet.2020.06.001

20. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. *Gut.* 2020;69:1545–1547. https://doi.org/10.1136/gutjnl-2020-321611

21. Forlano R, Mullish BH, Mukherjee SK, et al. In-hospital mortality is associated with inflammatory response in MAFLD patients admitted for COVID-19. *PLoS ONE.* 2020;15:e0240400. https://doi.org/10.1371/journal.pone.0240400

22. Polyzos SA, Kechagias S, Tsotchatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. *Aliment Pharmacol Ther.* 2021;54(8):1013–1025. https://doi.org/10.1111/apt.16575

23. Aksu E, Sokmen A, Ispiroglu M, Gisi K, Celik E, Aykan AC. Early cardiac electrical and structural changes in patients with non-obese non-alcoholic fatty liver disease. *Kardiologija.* 2021;61:51–58. https://doi.org/10.18087/cardio.2021.5.n1416

24. Serviddio G, Villani R, Stallone G, Scioscia G, Foschino-Barbaro MP, Lacedonia D. Tocilizumab and liver injury in patients with COVID-19. *Therap Adv Gastroenterol.* 2020;13:1756284820959183. https://doi.org/10.1177/1756284820959183

25. Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? *Expert Opin Drug Saf.* 2020;19:1367–1369. https://doi.org/10.1080/14740338.2020.1812191

26. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014;383:955–962. https://doi.org/10.1016/S0140-6736(13)62343-0

27. Li Y, Xiao SY. Hepatic involvement in COVID-19 patients: pathology, pathogenesis, and clinical implications. *J Med Virol.* 2020;92:1491–1494. https://doi.org/10.1002/jmv.25973

28. Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors. *Clin Infect Dis.* 2021;72:1256–1258. https://doi.org/10.1093/cid/ciaa883

29. Muhovic D, Bojovic J, Bulatovic A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. *Liver Int.* 2020;40:1901–1905. https://doi.org/10.1002/liv.14516

30. Lei F, Liu YM, Zhou F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. *Hepatology.* 2020;72:389–398. https://doi.org/10.1002/hep.31301

31. Alonso A, MacLehose RF, Chen LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. *Heart.* 2017;103:834–839. https://doi.org/10.1136/heartjnl-2016-310586

32. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. *Thromb Res.* 2020;192:152–160. https://doi.org/10.1016/j.thromres.2020.05.039

33. ESC guidance for the diagnosis and management of CVD during the COVID-19 pandemic – Updated 2021. https://www.escardio.org/Education/COVID-19-and-Cardiology

34. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. *Heart Rhythm.* 2020;17:1439–1444. https://doi.org/10.1016/j.hrthm.2020.06.016

35. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. *Eur Heart J.* 2020;41:1821–1829. https://doi.org/10.1093/eurheartj/ehaa388

36. Russo V, Rago A, Carbone A, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological implications. *J Cardiovasc Pharmacol.* 2020;76:138–145. https://doi.org/10.1097/FJC.0000000000000854

37. Arellano-Rodrigo E, Fernandez-Gallego V, Lopez-Vilchez I, et al. Idracucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemoStat. *Transfusion.* 2019;59:2436–2445. https://doi.org/10.1111/trf.15259
38. Listerri Caro JL, Cinza-Sanjurjo S, Polo Garcia J, Prieto Díaz MA. Use of direct-acting oral anticoagulants in Primary Care in Spain. Positioning statement by SEMERGEN on the current situation. Semergen. 2019;45:413–429. https://doi.org/10.1016/j.semerg.2019.06.002
39. Díaz-Guzmán J, Freixa-Pamias R, García-Alegría J, et al. Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018. Rev Esp Cardiol. 2021;81(S1):S185-S1857. https://doi.org/10.1016/j.rec.2021.07.009
40. Rivera-Izquierdo M, Valero-Uribeña MDC, Martínez-Díez S, et al. Clinical Factors, Preventive Behaviours and Temporal Outcomes Associated with COVID-19 Infection in Health Professionals at a Spanish Hospital. Int J Environ Res Public Health. 2020;17:4305. https://doi.org/10.3390/ijerph17124305
41. Interaction report. Liverpool Drug Interactions Group, University of Liverpool. www.covid19-druginteractions.org. Accessed August 28, 2021.
42. Maura G, Bardou M, Billionnet C, Weill A, Drouin J, Neumann A. Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. Sci Rep. 2020;10(1):11624. https://doi.org/10.1038/s41598-020-68304-8
43. Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic accuracy of FibroScan and factors affecting measurements. Diagnostics. 2020;10(1):753. https://doi.org/10.1007/s43991-020-00233-1
44. Testa S, Paoletti O, Giorgi-Pierfranceschi M, et al. Switch from oral anticoagulant to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15:751–753. https://doi.org/10.1007/s11739-020-02331-1
45. Schutgens RE. DOAC in COVID-19: yes or no? Hemasphere. 2020;5:e526. https://doi.org/10.1097/HS9.0000000000000526
46. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. https://doi.org/10.1056/NEJMoa0905561
47. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:883–891. https://doi.org/10.1056/NEJMoa1009638
48. Granger CB, Alexander JH, McMurry JJ, et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. https://doi.org/10.1056/NEJMoa1107039
49. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. https://doi.org/10.1056/NEJMoa1310907
50. Simpson BH, Reith DM, Medicott NJ, et al. Choice of renal function estimator influences adverse outcomes with dabigatran etexilate in patients with atrial fibrillation. TH Open. 2018;2:e420–e427. https://doi.org/10.1097/S0038-1676356
51. Yao X, Tangri Y, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:2621–2632. https://doi.org/10.1016/j.jacc.2017.09.1087
52. Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2019;34:265–277. https://doi.org/10.1093/ndt/gfy031
53. Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J. 2020;56:2001365. https://doi.org/10.1183/13993003.01365-2020
54. Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2020;298(2):E70–E80. https://doi.org/10.1148/radiol.2020203557
55. Sussen S, Tacquard CA, Godon A, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care. 2020;24:364. https://doi.org/10.1186/s13054-020-03000-7
56. Chowdhury JF, Moores LK, Conors JM. Anticoagulation in hospitalized patients with COVID-19. N Engl J Med. 2020;383:1675–1678. https://doi.org/10.1056/NEJMc12028217
57. Vivas D, Roldán V, Esteve-Pastor MA, et al. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev Esp Cardiol. 2020;73:749–757. https://doi.org/10.1016/j.recesp.2020.04.006
58. Guzik TJ, Mohiddin SA, Dimaro A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666–1687. https://doi.org/10.1093/cvr/cvaa106
59. Pardo Sanz A, Salido Táfores L, Ortega Pérez R, et al. New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis. Cardiol J. 2021;28:34–40. https://doi.org/10.5603/CJ.a2020.0145
60. De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced rate of Hospital Admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383:88–89. https://doi.org/10.1056/NEJMoa2009166
61. Holt A, Gislon G, Schou M, et al. New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. Eur Heart J. 2020;41:3072–3079. https://doi.org/10.1093/eurheartj/ehaa494